Hagiwara A, Takahashi T, Sawai K, Sakakura C, Yamaguchi M, Osaki K, Tsujimoto H, Ohyama T, Tomoda H, Yamamoto A
First Department of Surgery, Kyoto Prefectural University of Medicine, Japan.
Anticancer Drugs. 1994 Apr;5(2):194-8. doi: 10.1097/00001813-199404000-00009.
A new dosage formulation (MTX-CH) comprising methotrexate (MTX) adsorbed onto a suspension of activated carbon particles was developed for the treatment of lymph node metastases. In vitro studies showed that activated carbon particles adsorbed a great amount of MTX. Subcutaneous injection of MTX-CH into the left hind foot pad of rats distributed a greater amount of MTX selectively to the regional lymph nodes (the left popliteal node and the para-aortic nodes) for a longer period of time than similar administration of MTX aqueous solution with a smaller amount of MTX distributed to the rest of the whole body.
一种新的剂型（MTX-CH）被研发出来用于治疗淋巴结转移，该剂型由吸附在活性炭颗粒悬浮液上的甲氨蝶呤（MTX）组成。体外研究表明，活性炭颗粒吸附了大量的MTX。将MTX-CH皮下注射到大鼠的左后足垫，与注射甲氨蝶呤水溶液相比，MTX-CH能在更长时间内将更多的MTX选择性地分布到局部淋巴结（左腘窝淋巴结和主动脉旁淋巴结），而较少的MTX分布到全身其他部位。
